世界の抗ウイルス併用療法市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Antiviral Combination Therapies Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3843 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、抗ウイルス併用療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（NRTI / NNRTI、インテグラーゼ阻害剤/ NRTI、NRTI /プロテアーゼ阻害剤、その他）、用途別市場規模（HIV、肝炎、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・抗ウイルス併用療法の市場動向 ・企業の競争状況、市場シェア ・抗ウイルス併用療法の種類別市場規模と予測2016-2027（NRTI / NNRTI、インテグラーゼ阻害剤/ NRTI、NRTI /プロテアーゼ阻害剤、その他） ・抗ウイルス併用療法の用途別市場規模と予測2016-2027（HIV、肝炎、その他） ・抗ウイルス併用療法の北米市場規模2016-2027（アメリカ、カナダ） ・抗ウイルス併用療法の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・抗ウイルス併用療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・抗ウイルス併用療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・抗ウイルス併用療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Celltrion, Inc.、GlaxoSmithKline plc、Gilead Sciences, Inc.、AbbVie, Inc.、Bristol-Myers Squibb Company、Janssen Global Services、F. Hoffmann-La Roche Ltd.、Cipla, Inc.、Mylan N.V.、Merck & Co., Inc.） ・結論

The triple combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b holds promising potentials in the treatment of coronavirus (COVID-19). Researchers in healthcare companies and organizations are referring historical findings of the lopinavir-ritonavir & ribavirin combination, which was effective in lowering the morbidity and mortality rate of the then SARS (Severe Acute Respiratory Syndrome). Since COVID-19 is a novel viral infection, companies in the antiviral combination therapies market are increasing their research in triple combination therapies to advance in the coronavirus treatment.Many Coronavirus patients are in need for intensive respiratory support in hospitals. Since lopinavir–ritonavir and interferon beta-1b were found to reduce the viral load in SARS, companies in the antiviral combination therapies market are increasing focus in these drugs to innovate in antiviral drugs for coronavirus. It has been found that multiple antiviral drugs help to improve patient outcomes as compared to the consumption of single drug treatments.

Market Analysis and Insights: Global Antiviral Combination Therapies Market
The global Antiviral Combination Therapies market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antiviral Combination Therapies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antiviral Combination Therapies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antiviral Combination Therapies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antiviral Combination Therapies market.

Global Antiviral Combination Therapies Scope and Market Size
Antiviral Combination Therapies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antiviral Combination Therapies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
NRTI/NNRTI
Integrase Inhibitor/NRTI
NRTI/Protease Inhibitor
Others

Segment by Application
HIV
Hepatitis
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Celltrion, Inc.
GlaxoSmithKline plc
Gilead Sciences, Inc.
AbbVie, Inc.
Bristol-Myers Squibb Company
Janssen Global Services
F. Hoffmann-La Roche Ltd.
Cipla, Inc.
Mylan N.V.
Merck & Co., Inc.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antiviral Combination Therapies Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 NRTI/NNRTI
1.2.3 Integrase Inhibitor/NRTI
1.2.4 NRTI/Protease Inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antiviral Combination Therapies Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 HIV
1.3.3 Hepatitis
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Antiviral Combination Therapies Market Perspective (2016-2027)
2.2 Antiviral Combination Therapies Growth Trends by Regions
2.2.1 Antiviral Combination Therapies Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antiviral Combination Therapies Historic Market Share by Regions (2016-2021)
2.2.3 Antiviral Combination Therapies Forecasted Market Size by Regions (2022-2027)
2.3 Antiviral Combination Therapies Industry Dynamic
2.3.1 Antiviral Combination Therapies Market Trends
2.3.2 Antiviral Combination Therapies Market Drivers
2.3.3 Antiviral Combination Therapies Market Challenges
2.3.4 Antiviral Combination Therapies Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Antiviral Combination Therapies Players by Revenue
3.1.1 Global Top Antiviral Combination Therapies Players by Revenue (2016-2021)
3.1.2 Global Antiviral Combination Therapies Revenue Market Share by Players (2016-2021)
3.2 Global Antiviral Combination Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Antiviral Combination Therapies Revenue
3.4 Global Antiviral Combination Therapies Market Concentration Ratio
3.4.1 Global Antiviral Combination Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antiviral Combination Therapies Revenue in 2020
3.5 Antiviral Combination Therapies Key Players Head office and Area Served
3.6 Key Players Antiviral Combination Therapies Product Solution and Service
3.7 Date of Enter into Antiviral Combination Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Antiviral Combination Therapies Breakdown Data by Type
4.1 Global Antiviral Combination Therapies Historic Market Size by Type (2016-2021)
4.2 Global Antiviral Combination Therapies Forecasted Market Size by Type (2022-2027)

5 Antiviral Combination Therapies Breakdown Data by Application
5.1 Global Antiviral Combination Therapies Historic Market Size by Application (2016-2021)
5.2 Global Antiviral Combination Therapies Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Antiviral Combination Therapies Market Size (2016-2027)
6.2 North America Antiviral Combination Therapies Market Size by Type
6.2.1 North America Antiviral Combination Therapies Market Size by Type (2016-2021)
6.2.2 North America Antiviral Combination Therapies Market Size by Type (2022-2027)
6.2.3 North America Antiviral Combination Therapies Market Size by Type (2016-2027)
6.3 North America Antiviral Combination Therapies Market Size by Application
6.3.1 North America Antiviral Combination Therapies Market Size by Application (2016-2021)
6.3.2 North America Antiviral Combination Therapies Market Size by Application (2022-2027)
6.3.3 North America Antiviral Combination Therapies Market Size by Application (2016-2027)
6.4 North America Antiviral Combination Therapies Market Size by Country
6.4.1 North America Antiviral Combination Therapies Market Size by Country (2016-2021)
6.4.2 North America Antiviral Combination Therapies Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Antiviral Combination Therapies Market Size (2016-2027)
7.2 Europe Antiviral Combination Therapies Market Size by Type
7.2.1 Europe Antiviral Combination Therapies Market Size by Type (2016-2021)
7.2.2 Europe Antiviral Combination Therapies Market Size by Type (2022-2027)
7.2.3 Europe Antiviral Combination Therapies Market Size by Type (2016-2027)
7.3 Europe Antiviral Combination Therapies Market Size by Application
7.3.1 Europe Antiviral Combination Therapies Market Size by Application (2016-2021)
7.3.2 Europe Antiviral Combination Therapies Market Size by Application (2022-2027)
7.3.3 Europe Antiviral Combination Therapies Market Size by Application (2016-2027)
7.4 Europe Antiviral Combination Therapies Market Size by Country
7.4.1 Europe Antiviral Combination Therapies Market Size by Country (2016-2021)
7.4.2 Europe Antiviral Combination Therapies Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Antiviral Combination Therapies Market Size (2016-2027)
8.2 Asia-Pacific Antiviral Combination Therapies Market Size by Type
8.2.1 Asia-Pacific Antiviral Combination Therapies Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Antiviral Combination Therapies Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Antiviral Combination Therapies Market Size by Type (2016-2027)
8.3 Asia-Pacific Antiviral Combination Therapies Market Size by Application
8.3.1 Asia-Pacific Antiviral Combination Therapies Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Antiviral Combination Therapies Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Antiviral Combination Therapies Market Size by Application (2016-2027)
8.4 Asia-Pacific Antiviral Combination Therapies Market Size by Region
8.4.1 Asia-Pacific Antiviral Combination Therapies Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Antiviral Combination Therapies Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Antiviral Combination Therapies Market Size (2016-2027)
9.2 Latin America Antiviral Combination Therapies Market Size by Type
9.2.1 Latin America Antiviral Combination Therapies Market Size by Type (2016-2021)
9.2.2 Latin America Antiviral Combination Therapies Market Size by Type (2022-2027)
9.2.3 Latin America Antiviral Combination Therapies Market Size by Type (2016-2027)
9.3 Latin America Antiviral Combination Therapies Market Size by Application
9.3.1 Latin America Antiviral Combination Therapies Market Size by Application (2016-2021)
9.3.2 Latin America Antiviral Combination Therapies Market Size by Application (2022-2027)
9.3.3 Latin America Antiviral Combination Therapies Market Size by Application (2016-2027)
9.4 Latin America Antiviral Combination Therapies Market Size by Country
9.4.1 Latin America Antiviral Combination Therapies Market Size by Country (2016-2021)
9.4.2 Latin America Antiviral Combination Therapies Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Antiviral Combination Therapies Market Size (2016-2027)
10.2 Middle East & Africa Antiviral Combination Therapies Market Size by Type
10.2.1 Middle East & Africa Antiviral Combination Therapies Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Antiviral Combination Therapies Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Antiviral Combination Therapies Market Size by Type (2016-2027)
10.3 Middle East & Africa Antiviral Combination Therapies Market Size by Application
10.3.1 Middle East & Africa Antiviral Combination Therapies Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Antiviral Combination Therapies Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Antiviral Combination Therapies Market Size by Application (2016-2027)
10.4 Middle East & Africa Antiviral Combination Therapies Market Size by Country
10.4.1 Middle East & Africa Antiviral Combination Therapies Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Antiviral Combination Therapies Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Celltrion, Inc.
11.1.1 Celltrion, Inc. Company Details
11.1.2 Celltrion, Inc. Business Overview
11.1.3 Celltrion, Inc. Antiviral Combination Therapies Introduction
11.1.4 Celltrion, Inc. Revenue in Antiviral Combination Therapies Business (2016-2021)
11.1.5 Celltrion, Inc. Recent Development
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Company Details
11.2.2 GlaxoSmithKline plc Business Overview
11.2.3 GlaxoSmithKline plc Antiviral Combination Therapies Introduction
11.2.4 GlaxoSmithKline plc Revenue in Antiviral Combination Therapies Business (2016-2021)
11.2.5 GlaxoSmithKline plc Recent Development
11.3 Gilead Sciences, Inc.
11.3.1 Gilead Sciences, Inc. Company Details
11.3.2 Gilead Sciences, Inc. Business Overview
11.3.3 Gilead Sciences, Inc. Antiviral Combination Therapies Introduction
11.3.4 Gilead Sciences, Inc. Revenue in Antiviral Combination Therapies Business (2016-2021)
11.3.5 Gilead Sciences, Inc. Recent Development
11.4 AbbVie, Inc.
11.4.1 AbbVie, Inc. Company Details
11.4.2 AbbVie, Inc. Business Overview
11.4.3 AbbVie, Inc. Antiviral Combination Therapies Introduction
11.4.4 AbbVie, Inc. Revenue in Antiviral Combination Therapies Business (2016-2021)
11.4.5 AbbVie, Inc. Recent Development
11.5 Bristol-Myers Squibb Company
11.5.1 Bristol-Myers Squibb Company Company Details
11.5.2 Bristol-Myers Squibb Company Business Overview
11.5.3 Bristol-Myers Squibb Company Antiviral Combination Therapies Introduction
11.5.4 Bristol-Myers Squibb Company Revenue in Antiviral Combination Therapies Business (2016-2021)
11.5.5 Bristol-Myers Squibb Company Recent Development
11.6 Janssen Global Services
11.6.1 Janssen Global Services Company Details
11.6.2 Janssen Global Services Business Overview
11.6.3 Janssen Global Services Antiviral Combination Therapies Introduction
11.6.4 Janssen Global Services Revenue in Antiviral Combination Therapies Business (2016-2021)
11.6.5 Janssen Global Services Recent Development
11.7 F. Hoffmann-La Roche Ltd.
11.7.1 F. Hoffmann-La Roche Ltd. Company Details
11.7.2 F. Hoffmann-La Roche Ltd. Business Overview
11.7.3 F. Hoffmann-La Roche Ltd. Antiviral Combination Therapies Introduction
11.7.4 F. Hoffmann-La Roche Ltd. Revenue in Antiviral Combination Therapies Business (2016-2021)
11.7.5 F. Hoffmann-La Roche Ltd. Recent Development
11.8 Cipla, Inc.
11.8.1 Cipla, Inc. Company Details
11.8.2 Cipla, Inc. Business Overview
11.8.3 Cipla, Inc. Antiviral Combination Therapies Introduction
11.8.4 Cipla, Inc. Revenue in Antiviral Combination Therapies Business (2016-2021)
11.8.5 Cipla, Inc. Recent Development
11.9 Mylan N.V.
11.9.1 Mylan N.V. Company Details
11.9.2 Mylan N.V. Business Overview
11.9.3 Mylan N.V. Antiviral Combination Therapies Introduction
11.9.4 Mylan N.V. Revenue in Antiviral Combination Therapies Business (2016-2021)
11.9.5 Mylan N.V. Recent Development
11.10 Merck & Co., Inc.
11.10.1 Merck & Co., Inc. Company Details
11.10.2 Merck & Co., Inc. Business Overview
11.10.3 Merck & Co., Inc. Antiviral Combination Therapies Introduction
11.10.4 Merck & Co., Inc. Revenue in Antiviral Combination Therapies Business (2016-2021)
11.10.5 Merck & Co., Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Antiviral Combination Therapies Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of NRTI/NNRTI
Table 3. Key Players of Integrase Inhibitor/NRTI
Table 4. Key Players of NRTI/Protease Inhibitor
Table 5. Key Players of Others
Table 6. Global Antiviral Combination Therapies Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Antiviral Combination Therapies Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Antiviral Combination Therapies Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Antiviral Combination Therapies Market Share by Regions (2016-2021)
Table 10. Global Antiviral Combination Therapies Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Antiviral Combination Therapies Market Share by Regions (2022-2027)
Table 12. Antiviral Combination Therapies Market Trends
Table 13. Antiviral Combination Therapies Market Drivers
Table 14. Antiviral Combination Therapies Market Challenges
Table 15. Antiviral Combination Therapies Market Restraints
Table 16. Global Antiviral Combination Therapies Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Antiviral Combination Therapies Market Share by Players (2016-2021)
Table 18. Global Top Antiviral Combination Therapies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antiviral Combination Therapies as of 2020)
Table 19. Ranking of Global Top Antiviral Combination Therapies Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Antiviral Combination Therapies Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antiviral Combination Therapies Product Solution and Service
Table 23. Date of Enter into Antiviral Combination Therapies Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antiviral Combination Therapies Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Antiviral Combination Therapies Revenue Market Share by Type (2016-2021)
Table 27. Global Antiviral Combination Therapies Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Antiviral Combination Therapies Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Antiviral Combination Therapies Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Antiviral Combination Therapies Revenue Market Share by Application (2016-2021)
Table 31. Global Antiviral Combination Therapies Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Antiviral Combination Therapies Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Antiviral Combination Therapies Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Antiviral Combination Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Antiviral Combination Therapies Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Antiviral Combination Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Antiviral Combination Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Antiviral Combination Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Antiviral Combination Therapies Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Antiviral Combination Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Antiviral Combination Therapies Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Antiviral Combination Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Antiviral Combination Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Antiviral Combination Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Antiviral Combination Therapies Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Antiviral Combination Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Antiviral Combination Therapies Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Antiviral Combination Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Antiviral Combination Therapies Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Antiviral Combination Therapies Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Antiviral Combination Therapies Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Antiviral Combination Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Antiviral Combination Therapies Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Antiviral Combination Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Antiviral Combination Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Antiviral Combination Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Antiviral Combination Therapies Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Antiviral Combination Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Antiviral Combination Therapies Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Antiviral Combination Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Antiviral Combination Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Antiviral Combination Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 63. Celltrion, Inc. Company Details
Table 64. Celltrion, Inc. Business Overview
Table 65. Celltrion, Inc. Antiviral Combination Therapies Product
Table 66. Celltrion, Inc. Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 67. Celltrion, Inc. Recent Development
Table 68. GlaxoSmithKline plc Company Details
Table 69. GlaxoSmithKline plc Business Overview
Table 70. GlaxoSmithKline plc Antiviral Combination Therapies Product
Table 71. GlaxoSmithKline plc Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 72. GlaxoSmithKline plc Recent Development
Table 73. Gilead Sciences, Inc. Company Details
Table 74. Gilead Sciences, Inc. Business Overview
Table 75. Gilead Sciences, Inc. Antiviral Combination Therapies Product
Table 76. Gilead Sciences, Inc. Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 77. Gilead Sciences, Inc. Recent Development
Table 78. AbbVie, Inc. Company Details
Table 79. AbbVie, Inc. Business Overview
Table 80. AbbVie, Inc. Antiviral Combination Therapies Product
Table 81. AbbVie, Inc. Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 82. AbbVie, Inc. Recent Development
Table 83. Bristol-Myers Squibb Company Company Details
Table 84. Bristol-Myers Squibb Company Business Overview
Table 85. Bristol-Myers Squibb Company Antiviral Combination Therapies Product
Table 86. Bristol-Myers Squibb Company Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 87. Bristol-Myers Squibb Company Recent Development
Table 88. Janssen Global Services Company Details
Table 89. Janssen Global Services Business Overview
Table 90. Janssen Global Services Antiviral Combination Therapies Product
Table 91. Janssen Global Services Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 92. Janssen Global Services Recent Development
Table 93. F. Hoffmann-La Roche Ltd. Company Details
Table 94. F. Hoffmann-La Roche Ltd. Business Overview
Table 95. F. Hoffmann-La Roche Ltd. Antiviral Combination Therapies Product
Table 96. F. Hoffmann-La Roche Ltd. Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 97. F. Hoffmann-La Roche Ltd. Recent Development
Table 98. Cipla, Inc. Company Details
Table 99. Cipla, Inc. Business Overview
Table 100. Cipla, Inc. Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 101. Cipla, Inc. Recent Development
Table 102. Mylan N.V. Company Details
Table 103. Mylan N.V. Business Overview
Table 104. Mylan N.V. Antiviral Combination Therapies Product
Table 105. Mylan N.V. Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 106. Mylan N.V. Recent Development
Table 107. Merck & Co., Inc. Company Details
Table 108. Merck & Co., Inc. Business Overview
Table 109. Merck & Co., Inc. Antiviral Combination Therapies Product
Table 110. Merck & Co., Inc. Revenue in Antiviral Combination Therapies Business (2016-2021) & (US$ Million)
Table 111. Merck & Co., Inc. Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antiviral Combination Therapies Market Share by Type: 2020 VS 2027
Figure 2. NRTI/NNRTI Features
Figure 3. Integrase Inhibitor/NRTI Features
Figure 4. NRTI/Protease Inhibitor Features
Figure 5. Others Features
Figure 6. Global Antiviral Combination Therapies Market Share by Application: 2020 VS 2027
Figure 7. HIV Case Studies
Figure 8. Hepatitis Case Studies
Figure 9. Others Case Studies
Figure 10. Antiviral Combination Therapies Report Years Considered
Figure 11. Global Antiviral Combination Therapies Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Antiviral Combination Therapies Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Antiviral Combination Therapies Market Share by Regions: 2020 VS 2027
Figure 14. Global Antiviral Combination Therapies Market Share by Regions (2022-2027)
Figure 15. Global Antiviral Combination Therapies Market Share by Players in 2020
Figure 16. Global Top Antiviral Combination Therapies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antiviral Combination Therapies as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Antiviral Combination Therapies Revenue in 2020
Figure 18. Global Antiviral Combination Therapies Revenue Market Share by Type (2016-2021)
Figure 19. Global Antiviral Combination Therapies Revenue Market Share by Type (2022-2027)
Figure 20. North America Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Antiviral Combination Therapies Market Share by Type (2016-2027)
Figure 22. North America Antiviral Combination Therapies Market Share by Application (2016-2027)
Figure 23. North America Antiviral Combination Therapies Market Share by Country (2016-2027)
Figure 24. United States Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Antiviral Combination Therapies Market Share by Type (2016-2027)
Figure 28. Europe Antiviral Combination Therapies Market Share by Application (2016-2027)
Figure 29. Europe Antiviral Combination Therapies Market Share by Country (2016-2027)
Figure 30. Germany Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Antiviral Combination Therapies Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Antiviral Combination Therapies Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Antiviral Combination Therapies Market Share by Region (2016-2027)
Figure 40. China Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Antiviral Combination Therapies Market Share by Type (2016-2027)
Figure 48. Latin America Antiviral Combination Therapies Market Share by Application (2016-2027)
Figure 49. Latin America Antiviral Combination Therapies Market Share by Country (2016-2027)
Figure 50. Mexico Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Antiviral Combination Therapies Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Antiviral Combination Therapies Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Antiviral Combination Therapies Market Share by Country (2016-2027)
Figure 56. Turkey Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Antiviral Combination Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Celltrion, Inc. Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 60. GlaxoSmithKline plc Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 61. Gilead Sciences, Inc. Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 62. AbbVie, Inc. Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 63. Bristol-Myers Squibb Company Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 64. Janssen Global Services Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 65. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 66. Cipla, Inc. Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 67. Mylan N.V. Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 68. Merck & Co., Inc. Revenue Growth Rate in Antiviral Combination Therapies Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---